In this issue:
- Axial SpA in first-degree relatives of probands with AS
- Baricitinib for relapsed GCA
- Litifilimab for CLE
- Methotrexate in patients with arthralgia at risk of RA
- Severe COVID-19 outcome risk with IMIDs and immune-modifying therapies
- Factors associated with poor response to initial glucocorticoids in AOSD
- Comparison of amitriptyline and FDA-approved fibromyalgia treatments
- Intensive serum urate lowering in erosive gout
- Association of polygenic risk scores with radiographic progression in RA
- Nintedanib for autoimmune disease related progressive fibrosing ILDs
Please login below to download this issue (PDF)